Q-omics provides the consensus-scored RPL36A-HNRNPH2 profile across patient tissues and cancer cell-line models. RPL36A-HNRNPH2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL36A-HNRNPH2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RPL36A-HNRNPH2 RNA expression shows 11,478 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where RPL36A-HNRNPH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36A-HNRNPH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36A-HNRNPH2 survival associations across molecular data types. RPL36A-HNRNPH2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36A-HNRNPH2 RNA expression–survival associations across cancer types. High RPL36A-HNRNPH2 expression shows unfavorable associations in KIRP and UCEC, but favorable associations in MESO, LGG, ACC and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL36A-HNRNPH2 RNA expression.
This table summarizes RPL36A-HNRNPH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL36A-HNRNPH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36A-HNRNPH2 shows lower tumor expression in UCEC and higher tumor expression in KIRC, LIHC, LUSC, LUAD and KIRP. The KIRC box plot shows higher RPL36A-HNRNPH2 RNA expression in tumor versus normal tissue (log2 FC = +0.206, t-test p < 0.001).
This table shows molecular features associated with RPL36A-HNRNPH2 in patient tissues and cancer cell lines. In patient samples, RPL36A-HNRNPH2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL36A-HNRNPH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
